MUTEINS OF HUMAN LIPOCALIN 2 WITH AFFINITY FOR GLYPICAN-3 (GPC3)
1 Assignment
0 Petitions
Accused Products
Abstract
The present disclosure relates to novel, specific-binding therapeutic and/or diagnostic proteins directed against Glypican-3 (GPC3), which proteins preferably are muteins of a lipocalin protein, more preferably of lipocalin 2 (Lcn2 or NGAL). Present disclosure also relates to nucleic acid molecules encoding such proteins and to methods for generation and use of such proteins and nucleic acid molecules. Accordingly, present disclosure also is directed to pharmaceutical and/or diagnostic compositions comprising such lipocalin proteins, including uses of these proteins.
-
Citations
35 Claims
-
1-15. -15. (canceled)
-
16. A nucleic acid molecule comprising a nucleotide sequence encoding a human neutrophil gelatinase-associated lipocalin (hNGAL) mutein capable of binding glypican-3 (GPC3) with detectable affinity, wherein the mutein comprises a mutated amino acid residue at the sequence position 65 in comparison with the linear polypeptide sequence of mature hNGAL (SEQ ID NO:
- 1), and wherein the mutein has at least 85% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs;
5-16. - View Dependent Claims (17, 18, 19, 20, 21, 22, 23, 24, 25, 26)
- 1), and wherein the mutein has at least 85% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs;
-
27. An hNGAL mutein capable of binding GPC3 with detectable affinity, wherein the mutein comprises a mutated amino acid residue at the sequence position 65 in comparison with the linear polypeptide sequence of mature hNGAL (SEQ ID NO:
- 1), and wherein the mutein has at least 85% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs;
5-16. - View Dependent Claims (28, 29, 30, 31, 32, 33, 34, 35)
- 1), and wherein the mutein has at least 85% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOs;
Specification